Lenalidomide proved effective in multisystem Langerhans cell histiocytosis

• Authors: SZTURZ Petr; ADAM Zdeněk; ŘEHÁK Zdeněk; KOUKALOVÁ Renata; ŠLAISOVÁ Radka; STEHLÍKOVÁ Olga; CHOVANCOVÁ Jana; KLABUSAY Martin; KREJČÍ Marta; POUR Luděk; HÁJEK Roman; MAYER Jiří
• Year of publication: 2012
• Type: Article in Periodical
• Magazine / Source: Acta Oncologica
• MU Faculty or unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3109/0284186X.2011.631581
• Field: Oncology and hematology
• Keywords: Langerhans cell histiocytosis; lenalidomide; PET/CT
• Description: Langerhans cell histiocytosis (LCH) is a rare idiopathic disease with diverse clinical manifestations ranging from a single osteolytic lesion to generalized disease. Various treatment regimens have been proposed for the multisystem type, however, with inconsistent outcomes. Herein we are the first to report on a therapy effect of a lenalidomide-based regimen in a patient with repeatedly relapsed aggressive form of multisystem LCH.

Related projects

• University Research Centre - Czech Myeloma Group
• From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
• Stanovení hladiny cytokinů a kostimulačních molekul v plasmě, kostní dřeni, leukocytech a nádorových buňkách nemocných s hematologickými malignitami a jejich vztah k aktivitě nemoci, transplantaci krvetvorby, rozvoji komplikací (GvHD) a riziku relapsu
• Úloha mitotické disrupce v B lymfocytech u mnohočetného myelomu